Proteins and Antibodies for Conjugate Development: Selection Guide

Sep 14, 2026

Proteins and antibodies for conjugate development should be selected according to the target, label, assay format, molecular configuration and validation plan. A fluorescent antibody for flow cytometry requires different starting-material characteristics from an HRP-conjugated detection antibody or a biotinylated recombinant protein used in an immunoassay. The starting material can influence labeling efficiency, recovery and final assay performance. Protein purity, antibody specificity, buffer composition, available reactive groups, tag position and baseline activity should therefore be reviewed before conjugation begins.

Beta LifeScience offers recombinant target proteins, antibodies, biotinylated proteins, Avi-tagged proteins and phycobiliproteins that can support feasibility testing and conjugate-development workflows. Researchers requiring project-specific labeling, conjugation or functional testing can submit their requirements for technical evaluation and scope confirmation.

Beta LifeScience Products for Conjugate Development

Product or service	Available format	Potential use	Key purchasing check	Action
Biotinylated proteins	Ready-to-use biotinylated recombinant proteins	Capture assays, binding studies and streptavidin-based detection	Target, sequence, tag, biotinylation method and retained activity	Browse Biotinylated Proteins
Avi-tagged proteins	Recombinant proteins containing an Avi tag	Controlled enzymatic biotinylation and oriented immobilization	Avi-tag position, biotinylation status, purity and assay orientation	Browse Avi-Tagged Proteins
Phycobiliproteins	Fluorescent protein materials	Fluorescent-reagent development for flow cytometry and immunoassays	Fluorescence, purity, concentration and conjugation suitability	Browse Phycobiliproteins
Recombinant target proteins	Cytokines, receptors, CD antigens, immune-checkpoint proteins and other targets	Antibody screening, specificity testing, standards and controls	Sequence, species, expression host, tag, activity and formulation	Browse Recombinant Proteins
HRP-conjugated DXD monoclonal antibodies	BLC-06325A and BLC-06326A	ELISA development for DXD-containing targets	Product-specific binding data, buffer, application and assay response	View BLC-06325A or BLC-06326A
Custom protein expression and antibody production	Custom recombinant proteins and antibody-production routes	New targets, sequences, orthologs, mutants or project-specific starting materials	Sequence, host, tag, purification, quantity and analytical requirements	Protein Expression or Antibody Production

The HRP-conjugated DXD antibodies are combined because both catalog pages use similar product names and list ELISA as the application. Buyers should compare their product-specific functional binding data and confirm which reagent is better aligned with the intended DXD-containing analyte.

Buy Now

Choose the Right Purchasing Route

Selecting the purchasing route before extensive optimization helps ensure that the starting material used during feasibility testing can also support later assay development.

Purchasing route	Best suited for	What to confirm
Listed catalog conjugate	A catalog product whose target, label and validated application match the assay	Clone, conjugate, buffer, functional data and available size
Catalog protein or antibody	Laboratory conjugation and early feasibility testing	Purity, concentration, carrier content, preservatives and baseline activity
Biotinylated protein	Streptavidin-based capture or detection	Biotinylation method, labeling status and retained binding
Avi-tagged protein	Controlled enzymatic biotinylation	Tag location, biotinylation status and assay orientation
Semi-custom protein configuration	An existing protein requiring selected tag, buffer, concentration or packaging changes	Which catalog protein attribute requires modification
Custom protein expression or antibody production	New target, construct, species ortholog, mutant or antibody	Sequence, host, purification, quantity and testing expectations
Bulk or dedicated-lot supply	Validated assays moving into larger studies	Total usage, packaging, lot reservation and delivery schedule

Semi-custom configuration refers specifically to recombinant proteins. Antibody-production requirements and available deliverables should be defined separately during technical evaluation.

Planning a recombinant protein or antibody project for conjugate development?

Share your target, format, quantity, formulation and analytical requirements through the project-evaluation form.

Select the Starting Material by Assay Format

The final detection system determines which protein, antibody and label format should be purchased.

Flow cytometry

Direct flow cytometry uses a target-specific antibody carrying a fluorophore. It supports shorter staining workflows and is well suited to multiplex panels in which each antibody is assigned to a separate detection channel. Selection should account for antibody clone, target abundance, instrument lasers, detector filters, sample autofluorescence and spectral overlap. Bright fluorophores are often evaluated for lower-abundance targets, while highly expressed markers can use more moderate signals. Indirect flow cytometry uses an unconjugated primary antibody followed by a fluorescent secondary reagent. This provides flexibility during early screening because multiple primary antibodies can be compared using a compatible secondary reagent. Once the preferred clone is selected, direct labeling can provide a more defined format for complex panels. For either route, review the antibody buffer before purchasing. Carrier proteins, preservatives and reactive additives can influence conjugation efficiency.

Sandwich immunoassays

A sandwich immunoassay combines a capture antibody, target analyte and detection antibody. The antibody pair should recognize compatible epitopes and perform under the same buffer and matrix conditions. The detection antibody may be enzyme-conjugated, biotinylated or detected with a labeled secondary reagent. Recombinant target proteins can support pairing studies, calibration, specificity testing, spike recovery and positive controls.

Competitive immunoassays

Competitive assays may use a labeled antigen, analyte analog or antibody. They are useful when the target is small or has limited accessible epitopes. The recombinant target or conjugated antigen should reproduce the binding feature recognized by the antibody. Labeling density and linker placement can affect competitive behavior, so the final conjugate should be evaluated in the complete assay.

Select the Label and Molecular Format

Label or format	Typical use	Main purchasing consideration
Small-molecule fluorophore	Flow cytometry and fluorescence immunoassays	Brightness, photostability and spectral compatibility
Phycobiliprotein	Bright flow-cytometry detection	Molecular size, purity, light protection and stability
Biotin	Capture, detection and signal-amplification workflows	Biotin density and streptavidin compatibility
Avi-tag-mediated biotin	Controlled biotinylation and oriented capture	Tag position and actual biotinylation status
HRP	Colorimetric or chemiluminescent immunoassays	Enzyme activity, substrate system and formulation
Unconjugated protein or antibody	Early feasibility and indirect detection	Purity, concentration, buffer and biological activity

Fluorescent materials

Fluorophore selection should be completed within the context of the full flow panel. Target co-expression and spectral overlap can affect population separation even when each reagent performs well individually. Phycobiliproteins such as R-phycoerythrin provide bright fluorescence for flow-cytometry applications. Their comparatively large molecular structure makes purity, coupling strategy, purification and light-protected storage important purchasing considerations. Researchers can review Beta LifeScience’s phycobiliprotein collection and confirm the exact product form, concentration and conjugation suitability before ordering.

Biotinylated and Avi-tagged proteins

Ready-to-use biotinylated proteins can simplify streptavidin-based capture and detection. They can support ELISA, interaction studies and selected flow workflows. An Avi-tagged protein is a different starting format. It contains a defined peptide sequence that can support enzymatic biotinylation. This approach can provide controlled label placement and oriented capture when the tag remains accessible. Before ordering, confirm whether the product is already biotinylated or contains an Avi tag for subsequent processing.

HRP-conjugated antibodies

HRP conjugates support colorimetric and chemiluminescent immunoassays. Their performance reflects both antigen recognition and enzyme activity.

Beta LifeScience lists two HRP-conjugated DXD monoclonal antibodies:

Both are listed for ELISA and include individual functional binding data. The final selection should be based on performance with the intended DXD-containing target and sample matrix.

Is the Starting Material Conjugation-Ready?

A conjugation-ready material has appropriate purity, concentration and formulation for the selected chemistry.

Purity and functional quality

Impurities can consume labeling reagent and complicate final purification. Review available SDS-PAGE, chromatography, identity, binding or activity data before purchasing. Affinity-purified antibodies are often useful starting materials. Recombinant proteins should also be checked for sequence boundaries, expression host, tag and oligomeric format.

Buffer and concentration

Amine-containing buffers can compete during amine-reactive labeling. Reducing agents influence thiol-directed reactions, while sodium azide can interfere with HRP activity. BSA or gelatin may also react with labeling reagents.

Review the formulation for:

Carrier proteins
Tris, glycine or other free amines
Sodium azide
Glycerol
Reducing agents
Detergents
Stabilizers and preservatives

Buffer exchange can prepare a suitable protein or antibody for conjugation. The material should also be concentrated enough to support efficient processing and recovery.

Molecular configuration

Tags and fusion partners affect orientation, molecular weight and purification. His, Fc and Avi tags serve different purposes and should be selected according to the assay. A soluble extracellular domain can support antibody screening and immunoassays. For flow cytometry, binding should also be evaluated with the target presented in the intended cellular context.

Match the Material to the Conjugation Strategy

Amine-reactive chemistry commonly targets lysine residues and the protein N-terminus. It is widely used for fluorophore and biotin attachment, although the final conjugate generally contains a distribution of labeled molecules. The starting buffer should be free from competing primary amines. Thiol-reactive chemistry targets available sulfhydryl groups and can support more controlled coupling when a suitable cysteine is available. Antibody reduction conditions should preserve the structural and binding characteristics required by the assay. Avi-tag-mediated biotinylation provides a defined labeling site. It is useful when oriented capture or consistent biotin placement is important. Success begins with selecting a construct in which the tag remains accessible without disrupting the target’s required binding surface.

Define the Analytical Package

Quality attribute	Question addressed	Potential assessment
Identity	Is the correct protein or antibody present?	Mass spectrometry or immunochemical testing
Purity	Are major contaminants detectable?	SDS-PAGE or chromatography
Concentration	How much material is available?	UV absorbance or a suitable protein assay
Aggregation	Is the material predominantly monomeric?	SEC-HPLC or another size-based method
Label incorporation	Was the label attached at a useful level?	Dual-wavelength or label-specific analysis
Binding or activity	Does the material retain its required function?	ELISA, flow cytometry, binding or activity assay
Stability	Does performance remain consistent during storage?	Defined time-point testing

The appropriate package depends on the development stage and assay risk. Requested analytical methods and acceptance criteria should be reviewed during technical evaluation.

Need a project-specific analytical package?

Share your required identity, purity, aggregation, binding and activity assessments through the project-evaluation form.

Validate the Material in the Final Assay

Analytical characterization shows that the material meets selected physical or chemical criteria. Final assay testing determines whether it performs in the intended application. For flow cytometry, titrate the fluorescent antibody using relevant positive and negative cells. Review population separation, background and performance in the complete multicolor panel. Include the controls required for compensation, spectral unmixing and reliable gating. For ELISA or another immunoassay, evaluate blank signal, positive signal, calibration response, precision, working range and matrix behavior. Serum, plasma and cell-culture supernatants can affect background and apparent analyte recovery. A recombinant target can support calibration when its sequence, molecular format and assay response appropriately represent the intended measurand.

Plan Quantity, Packaging and Lot Continuity

Quantity planning should cover starting-material qualification, buffer exchange, conjugation screening, purification, analytical testing, assay optimization, repeats and future lot bridging. Once a suitable format is identified, bulk or dedicated-lot purchasing can support longer studies. Packaging should match the planned reaction scale and storage schedule, while sufficient material should be reserved to compare future lots. For custom proteins, concentration, formulation and packaging requirements can be discussed during project evaluation. For antibodies, production and purification options should be confirmed without assuming that conjugation is automatically included.

How Beta LifeScience Can Support the Project

Beta LifeScience can support conjugate-development workflows through its confirmed recombinant protein, antibody and specialized starting-material offerings. Researchers can begin with a catalog biotinylated protein, Avi-tagged construct, phycobiliprotein, recombinant target or listed HRP-conjugated DXD antibody. When the required target or configuration is unavailable, Beta LifeScience can evaluate custom protein expression or antibody production.

Frequently Asked Questions

What support is available for a custom conjugate-development project?

Beta LifeScience offers recombinant proteins, antibodies, biotinylated proteins, Avi-tagged proteins, phycobiliproteins, custom protein expression and antibody production. Researchers can submit their labeling, conjugation and analytical requirements for technical review and confirmation of the available project scope.

What is the difference between a biotinylated protein and an Avi-tagged protein?

A biotinylated protein already carries biotin. An Avi-tagged protein contains a defined sequence that supports enzymatic biotinylation. Confirm the product’s actual biotinylation status before ordering.

Which starting material is suitable for flow cytometry?

Select an antibody with suitable specificity, purity, concentration and buffer. The intended fluorophore should also match the target abundance, instrument and complete staining panel.

Can a recombinant protein be used as an immunoassay standard?

Yes, when its sequence, molecular format, concentration assignment and assay response appropriately represent the measurand. Matrix behavior and commutability may require additional evaluation.

Why does the starting buffer matter?

Carrier proteins, free amines, reducing agents and preservatives can interact with labeling chemistry or the final detection system. Reviewing the buffer identifies whether exchange is required.

When should bulk material be requested?

Bulk supply becomes useful after the protein or antibody format is selected and total consumption is calculated. Include optimization, processing losses, validation and lot-bridging material.

Conclusion:

A strong conjugate project begins with a protein or antibody that matches the target, label, assay platform, formulation and validation plan. Defining these requirements before ordering supports efficient feasibility testing and future scale-up. Request Protein or Antibody Support for Your Conjugate Project Include the target name or sequence, species, desired protein or antibody format, intended label, assay platform, quantity, formulation and analytical expectations for a focused feasibility assessment and quotation.